Markets:

Overview

News

Currencies

International

Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CymaBay Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

5 Most Expensive Health Care Stocks You Should Worry About ↗

January 03, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

CymaBay Therapeutics: Q2 Earnings Insights ↗

August 11, 2022

CymaBay Therapeutics (NASDAQ:CBAY) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:06 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Outlook For CymaBay Therapeutics ↗

August 10, 2022

CymaBay Therapeutics (NASDAQ:CBAY) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement.

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 27, 2022

Via Benzinga

CymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free Survival ↗

May 23, 2022

Via Benzinga

CymaBay Therapeutics: Q1 Earnings Insights ↗

May 12, 2022

CymaBay Therapeutics (NASDAQ:CBAY) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More ↗

June 23, 2022

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.

Via Benzinga

38 Stocks Moving In Tuesday's Mid-Day Session ↗

June 07, 2022

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) gained 70% to $0.4900 after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic's Gamma...

Via Benzinga

79 Biggest Movers From Yesterday ↗

June 08, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it...

Via Benzinga

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗

May 22, 2022

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 18, 2022

Via Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗

May 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 22, 2022

Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 94.7% to $2.2 during Friday's pre-market session. The company's market cap stands at $14.9 million.

Via Benzinga

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗

March 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

CymaBay Therapeutics: Q4 Earnings Insights ↗

March 17, 2022

CymaBay Therapeutics (NASDAQ:CBAY) reported its Q4 earnings results on Thursday, March 17, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data ↗

March 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

A Preview Of CymaBay Therapeutics's Earnings ↗

March 16, 2022

CymaBay Therapeutics (NASDAQ:CBAY) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement....

Via Benzinga

Earnings Scheduled For March 17, 2022 ↗

March 17, 2022

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is...

Via Benzinga

Mid-Afternoon Market Update: Crude Oil Drops 2%; Limelight Networks Shares Spike Higher ↗

January 21, 2022

Toward the end of trading Friday, the Dow traded down 0.59% to 34,509.34 while the NASDAQ fell 1.38% to 13,958.13. The S&P also fell, dropping, 0.99% to 4,438.28. The U.S. has...

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Mid-Day Market Update: Dow Falls 100 Points; Netflix Shares Plummet ↗

January 21, 2022

Midway through trading Friday, the Dow traded down 0.33% to 34,602.05 while the NASDAQ fell 1.27% to 13,974.28. The S&P also fell, dropping, 0.75% to 4,449.20. The U...

Via Benzinga

34 Stocks Moving In Friday's Mid-Day Session ↗

January 21, 2022

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life Limited (NASDAQ: BON) shares gained 22% to $3.91....

Via Benzinga

Mid-Morning Market Update: Markets Down; Schlumberger Earnings Top Views ↗

January 21, 2022

Following the market opening Friday, the Dow traded down 0.24% to 34,632.21 while the NASDAQ fell 1.37% to 13,959.79. The S&P also fell, dropping, 0.88% to 4,443.39. The U.S....

Via Benzinga

4 Penny Stocks Insiders Are Buying: CymaBay Therapeutics, Avalo Therapeutics And More ↗

January 21, 2022

US stock futures traded lower this morning after Netflix, Inc. (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings ↗

November 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...

Via Benzinga

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

CymaBay Therapeutics Inc. (CBAY) Q3 2021 Earnings Call Transcript ↗

November 11, 2021

CBAY earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 06, 2021

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a...

Via Benzinga

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

Headline News about CymaBay Therapeutics Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today